OPEN TO ENROLLMENT Protocol	***Status***	***Ages***	***Inclusion / Exclusion***
Sponsor/Study Name/Study number: Neurelis/ "An Open Label, Single-Dose, Pharmacokinetics Study of VALTOCO with Open-Label safety period in Pediatric Subjects with Epilepsy **DIAZ01** PI – Dr Segal VALTOCO	Open to enrollment	2-5yrs old	✓ Must use their rescue a least once in the past 3 months
Sponsor/Study Name/Study number: Cerevel Therapeutics, LLC/" A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Trial of CVL-865 as Adjunctive Therapy in Adults with Drug-Resistant Focal Onset Seizures (REALIZE)" **CVL-865-SZ-001** PI – Dr Segal / Sub-I Dr Rafiuddin	Open to enrollment	18-75yr.	✓Dx POS / Focal 2 yrs. ago ✓or more seizures a month x 3 months prior to baseline ✓Failed 2 AEDs in the past ✓Excluded if presently on Tegretol, Aptiom, Trileptal or Dilantin
Sponsor/Study Name: Equilibre/ "A Dose-Ranging Safety, Tolerability, and Exploratory Efficacy Study of Adjunctive EQU-001 for Seizures in Adults with Epilepsy **EQU-201** PI – Dr Rafiuddin / Sub -I Dr Segal IVERMECTIN	Closed to Enrollment	18 -60 yr.	✓Dx with epilepsy and with uncontrolled countable seizures ✓May be on 1 to 4 AEDS ✓Must have 3 countable seizures 4 weeks prior to baseline ✓ Seizures may be generalized or focal . May not include absence or focal without motor involvement, aphasia or other observable symptom.
Sponsor/Study Name SK Life/ "A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures**"** **YKP3089CO25** PI – Dr Segal- PEDS / Sub-I Dr Rafiuddin-Adults XCOPRI	OPEN To Enrollment	12-60yr	✓DX PGTC seizures ✓Must have 5 PGTC seizures 12 weeks prior to baseline ✓May be on 1 to 3 AEDS ✓VNS must be implanted a least 5 months prior to baseline ✓Excluded if they also have POS seizures or LGS DX

OPEN TO ENROLLMENT Protocol	***Status***	***Ages***	***Inclusion / Exclusion***
Sponsor/Study Name SK Life/A phase 1, open label pharmacokentic dose escalation study of Cenobamate (YKP3089) in Pediatric Subjects with POS.**YKP3089C039** PI – Dr Segal- PEDS XCOPRI	6-<12 Cohort 2 Will open end of November	4-<6 Cohort 3 2-<4 Cohort 4	✓ DX POS ✓ Failed 2 previous AEDs ✓ May be on 1 to 3 AEDS ✓ If on Onfi must be off a least 30 days prior to Day 1 ✓ Offsite for in unit PKs draws from Day -1 - Day 4.
Sponsor/Study Name: SK Life/" A Randomized, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated with Lennox-Gastaut Syndrome in Children and Adults, with Optional Open-Label Extension" YKP509 -- **YKP509COO3** PI – Dr Segal / Sub-I Dr Rafiuddin CARISBAMATE	OPEN To Enrollment	4-55 yr.	✓Documented HX of LGS ✓Must have evidence of more than one type of seizure ✓One of those seizure types must be either drop (atonic / tonic) or tonic-clonic seizures 6 months prior to baseline ✓Drop seizures must have 2 with the potential to fall or tonic clonic seizures per week during the 4 wk baseline period ✓Onset of LGS must be < 11 yrs. old May be on 1 to 4 AEDS
Sponsor/Study Name: SK Life/ "Open-Label Safety and Efficacy Study of Cenbamate (YKP3089) in Pediatric Subjects with Partial-onset (Focal) Seizures**" YKP3089C040** PI – Dr Segal XCOPRI	Open now for 039 patients	12-17 yr. Will open at the end of November	✓DX with POS (Focal) ✓May be on 1 to 3 AEDS ✓Must have one POS within 8 weeks prior to baseline
Sponsor/Study Name: Equilibre/A Randomized Phase 2 Study of Adjunctive EQU-001 for Uncontrolled Focal Onset Seizures **EQU-202** PI – Dr Rafiuddin-Adults /Sub -I Dr Segal-PEDS IVERMECTIN	OPEN	18-65yr	✓DX with POS (Focal). May not include focal aware seizures without a detectable motor component, aphasia or other observable symptom. ✓May be on 1 to 3 AEDS ✓Must have 4 countable Focal seizures a month ✓

Protocol	*Status*	*Ages*	*Inclusion / Exclusion*
Sponsor/Study Name: Marinus Pharmaceuticals/ A phase 3,double blind randomized placebo controlled trial of adjunctive Ganaxolone (GNX) treatment in children and Adults with Tuberous Sclerosis Complex(TSC) related Epilepsy (TRUSTTSC)**1042-TSC-3001** PI – Dr Rafiuddin-Adults /Sub -I Dr Segal-PEDS	OPEN	1-65yr	Clinical or mutational diagnosis of TSC ✓ Molecular confirmation or clinical diagnosis ✓ Failed a least 2 AEDs ✓ 8 countable seizures per month in the 2 months before screening
Sponsor/Study Name: Xenon Pharmaceuticals / A Randomized, Double-Blind Placebo-controlled multicenter Phase 3 Study to Evaluate the safety tolerability and efficacy of XEN1101 as adjunctive Therapy in focal -onset Epilepsy **XPF-008-301** PI – Dr Rafiuddin-Adults	SIV 11/1	18-75yr	✓ DX with POS (Focal) ✓ HX of only focal aware without motor seizures only will not be allowed ✓ May be on 1 to 3 AEDS ✓ During the 8-week baseline period must have more than 4 focal seizures within 28 days
Sponsor/Study Name/Study number: Eisai/" An Open-Label Study with Extension Phase to Evaluate the Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Subjects (Age 1 Month to Less than 18 Years) with Childhood Epilepsy" **E2007-G000-236** PI – Dr Segal FYCOMPA	CLOSED	1-18yr.	✓

LB 10/28/22